In recent trading session, Prime Medicine Inc (NASDAQ:PRME) saw 0.35 million shares changing hands at last check today with its beta currently measuring 1.89. Company’s recent per share price level of $1.63 trading at -$0.16 or -8.94% at last check today assigns it a market valuation of $213.79M. That most recent trading price of PRME’s stock is at a discount of -407.36% from its 52-week high price of $8.27 and is indicating a discount of -1.23% from its 52-week low price of $1.65. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.4 million shares which gives us an average trading volume of 1.16 million if we extend that period to 3-months.

For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.31 in the current quarter.

Prime Medicine Inc (NASDAQ:PRME) trade information

Upright in the red during last session for losing -8.94%, in the last five days PRME remained trading in the red while hitting it’s week-highest on Tuesday, 04/01/25 when the stock touched $1.63 price level, adding 22.75% to its value on the day. Prime Medicine Inc’s shares saw a change of -44.18% in year-to-date performance and have moved -18.50% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of -29.44% in past 30-days. Number of shares sold short was 19.41 million shares which calculate 14.73 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 90.41% to its recent value today. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -636.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of -636.2% for stock’s current value.

Prime Medicine Inc (PRME) estimates and forecasts

This year revenue growth is estimated to rise 560.21% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.43M for the same. And 9 analysts are in estimates of company making revenue of 3.39M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -124.13% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 27.26% while estimates for its earnings growth in next 5 years are of 12.59%.

Prime Medicine Inc (NASDAQ:PRME)’s Major holders

Insiders are in possession of 23.91% of company’s total shares while institution are holding 59.07 percent of that, with stock having share float percentage of 77.63%. Investors also watch the number of corporate investors in a company very closely, which is 59.07% institutions for Prime Medicine Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at PRME for having 15.06 million shares of worth $77.42 million. And as of 2024-06-30, it was holding 12.6375 of the company’s outstanding shares.

The second largest institutional holder is ARK INVESTMENT MANAGEMENT LLC, which was holding about 6.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.1404 of outstanding shares, having a total worth of $31.49 million.

On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF and ARK ETF Trust-ARK Innovation ETF are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025, the former fund manager was holding 2.59 shares of worth $4.18 million or 1.98% of the total outstanding shares. The later fund manager was in possession of 2.17 shares on Feb 28, 2025, making its stake of worth around $3.51 million in the company or a holder of 1.66% of company’s stock.